IMMUNIC, Inc. (IMUX) intrinsic value & 10-year financials
IMMUNIC, Inc. (IMUX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $6.97
- Market cap
- $1.1B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 380.4%
- Free cash flow (FY2025)
- -$86.0M
IMUX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$97.2M | -$0.62 | -$86.0M | — | 529.0% |
| FY2024 | — | -$100.5M | -$1.00 | -$85.0M | — | 589.8% |
| FY2023 | — | -$93.6M | -$2.11 | -$71.2M | — | 2041.0% |
| FY2022 | — | -$120.4M | -$3.78 | -$65.3M | — | -493.8% |
| FY2021 | — | -$92.9M | -$3.93 | -$83.3M | — | -255.2% |
| FY2020 | — | -$44.0M | -$2.81 | -$46.3M | — | -143.1% |
| FY2019 | $0 | -$34.9M | — | -$28.6M | — | -243.8% |
| FY2018 | $0 | -$41.5M | — | -$43.8M | — | 1083.7% |
| FY2017 | — | -$52.1M | — | -$41.1M | — | 766.1% |
| FY2016 | — | -$41.0M | — | -$36.3M | — | -70.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
IMMUNIC, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
IMMUNIC, INC. has historically struggled to out-earn its cost of capital, averaging just -11.4% ROIC.
IMMUNIC, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
IMMUNIC, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.